First Trust Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $297K | Sell |
14,198
-2,444
| -15% | -$55K | ﹤0.01% | 2463 |
|
|
2025
Q4 | $383K | Sell |
16,642
-19,692
| -54% | -$648K | ﹤0.01% | 2397 |
|
|
2025
Q3 | $1.09M | Buy |
36,334
+22,345
| +160% | +$670K | ﹤0.01% | 2073 |
|
|
2025
Q2 | $509K | Sell |
13,989
-2,517
| -15% | -$90.7K | ﹤0.01% | 2262 |
|
|
2025
Q1 | $598K | Sell |
16,506
-527,696
| -97% | -$22M | ﹤0.01% | 2180 |
|
|
2024
Q4 | $22.9M | Buy |
544,202
+527,180
| +3,097% | +$26.2M | 0.02% | 806 |
|
|
2024
Q3 | $946K | Sell |
17,022
-264,071
| -94% | -$13.5M | ﹤0.01% | 2031 |
|
|
2024
Q2 | $11.6M | Sell |
281,093
-87,126
| -24% | -$3.72M | 0.01% | 968 |
|
|
2024
Q1 | $17.2M | Sell |
368,219
-794,858
| -68% | -$37.5M | 0.02% | 852 |
|
|
2023
Q4 | $55.6M | Sell |
1,163,077
-38,611
| -3% | -$1.5M | 0.06% | 408 |
|
|
2023
Q3 | $42.8M | Buy |
1,201,688
+46,852
| +4% | +$1.86M | 0.05% | 463 |
|
|
2023
Q2 | $53.3M | Sell |
1,154,836
-57,780
| -5% | -$2.68M | 0.06% | 431 |
|
|
2023
Q1 | $48.6M | Buy |
1,212,616
+68,644
| +6% | +$2.95M | 0.06% | 453 |
|
|
2022
Q4 | $53M | Buy |
1,143,972
+459,628
| +67% | +$18.1M | 0.06% | 438 |
|
|
2022
Q3 | $28.3M | Buy |
684,344
+118,699
| +21% | +$6.1M | 0.04% | 566 |
|
|
2022
Q2 | $33.7M | Sell |
565,645
-158,113
| -22% | -$9.73M | 0.04% | 536 |
|
|
2022
Q1 | $52.6M | Sell |
723,758
-18,883
| -3% | -$1.31M | 0.05% | 489 |
|
|
2021
Q4 | $62.4M | Buy |
742,641
+25,533
| +4% | +$2.08M | 0.06% | 440 |
|
|
2021
Q3 | $64.7M | Buy |
717,108
+123,165
| +21% | +$11.1M | 0.07% | 374 |
|
|
2021
Q2 | $56.6M | Buy |
593,943
+35,364
| +6% | +$3.68M | 0.06% | 441 |
|
|
2021
Q1 | $63.6M | Sell |
558,579
-205,226
| -27% | -$27.9M | 0.08% | 361 |
|
|
2020
Q4 | $106M | Sell |
763,805
-173,709
| -19% | -$20.6M | 0.14% | 181 |
|
|
2020
Q3 | $77.1M | Sell |
937,514
-234,195
| -20% | -$19.4M | 0.12% | 205 |
|
|
2020
Q2 | $91.7M | Buy |
1,171,709
+225,205
| +24% | +$14.9M | 0.16% | 149 |
|
|
2020
Q1 | $42.1M | Sell |
946,504
-241,459
| -20% | -$12.5M | 0.1% | 348 |
|
|
2019
Q4 | $50.7M | Buy |
1,187,963
+188,797
| +19% | +$7.79M | 0.09% | 349 |
|
|
2019
Q3 | $42.7M | Sell |
999,166
-516,029
| -34% | -$28M | 0.08% | 363 |
|
|
2019
Q2 | $96.2M | Sell |
1,515,195
-343,857
| -18% | -$21.9M | 0.18% | 135 |
|
|
2019
Q1 | $129M | Buy |
1,859,052
+387,118
| +26% | +$22.1M | 0.26% | 79 |
|
|
2018
Q4 | $64M | Buy |
1,471,934
+208,468
| +16% | +$11.4M | 0.15% | 154 |
|
|
2018
Q3 | $96.5M | Buy |
1,263,466
+285,961
| +29% | +$23.3M | 0.18% | 123 |
|
|
2018
Q2 | $75.1M | Buy |
977,505
+16,713
| +2% | +$1.08M | 0.16% | 131 |
|
|
2018
Q1 | $49M | Buy |
960,792
+175,098
| +22% | +$8.82M | 0.11% | 195 |
|
|
2017
Q4 | $36.4M | Buy |
785,694
+259,816
| +49% | +$12.7M | 0.09% | 295 |
|
|
2017
Q3 | $28M | Buy |
525,878
+14,138
| +3% | +$838K | 0.07% | 338 |
|
|
2017
Q2 | $31.8M | Buy |
511,740
+118,073
| +30% | +$7.11M | 0.08% | 287 |
|
|
2017
Q1 | $26.7M | Sell |
393,667
-7,820
| -2% | -$596K | 0.07% | 345 |
|
|
2016
Q4 | $28.2M | Buy |
+401,487
| New | +$28.5M | 0.08% | 299 |
|
|
2016
Q1 | – | Sell |
-28,063
| Closed | -$3.15M | – | 2275 |
|
|
2015
Q4 | $3.15M | Buy |
28,063
+147
| +0.5% | +$14.7K | 0.01% | 1161 |
|
|
2015
Q3 | $2.69M | Buy |
+27,916
| New | +$3.2M | 0.01% | 1237 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
First Trust Advisors's RARE Position: Q1 2026 in Review
First Trust Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 15% in Q1 2026, selling an estimated $55K and leaving 14,198 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #2463.
First Trust Advisors first reported a position in RARE in Q3 2015 and has held it in 40 quarters since. The position peaked at $129M in Q1 2019. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- First Trust Advisors held 14,198 shares of Ultragenyx Pharmaceutical worth $297K as of Q1 2026.
- First Trust Advisors sold 2,444 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $55K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of First Trust Advisors's portfolio in Q1 2026, its #2463 holding.
- First Trust Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and has held it in 40 quarters since.
- First Trust Advisors's Ultragenyx Pharmaceutical position peaked at $129M in Q1 2019.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.